Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. What Happens If You Use Expired Semaglutide? Wondering what ...

I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion. Sales increased by 5 ...

If you miss a dose of your weight loss or type 2 diabetes GLP-1 medication, you may not feel any differently right away, says Cecilia Low Wang, MD, a professor of medicine and director of the Glucose ...

Listen to more stories on the Noa app. Sign up for Being Human, our newsletter that explores wellness culture, human behavior, mortality and disease, and other mysteries of the body and the mind. An ...

Wegovy, the semaglutide-based weight loss medication, has become a pivotal choice for people in the UK seeking medical support for obesity, especially following the recent price increases for ...

Ozempic (semaglutide) is a prescription medication approved by the Food and Drug Administration (FDA) for adults with type 2 diabetes. It helps lower blood sugar levels, slow digestion, and suppress ...

The Central Drugs Standard Control Organization (CDSCO) has granted approval to Novo Nordisk’s blockbuster drug, Ozempic (Semaglutide injection), for use in India. The approval, announced on September ...

Ozempic Insulin box and injection pen or insulin cartridge pen for diabetes patients from Novo Nordisk. Blurred pharmacy background. Copenhagen, Denmark - January 29, 2024. A semaglutide pill is ...